Benitec Biopharma Limited (NASDAQ:BNTC) spotted trading -80.36% off 52-week high price. On the other end, the stock has been noted 46.56% away from the low price over the last 52-weeks. The stock changed -10.31% to recent value of $4.05. The stock transacted 6005 shares during most recent day however it has an average volume of 74.33K shares. The company has 1.61M of outstanding shares and 0.91M shares were floated in the market.
On April 14, 2020, Benitec Biopharma Limited (NASDAQ:BNTC) a development-stage biotechnology company focused on the advancement of novel genetic medicines, released the appointment of Edward Smith to the Board of Directors.
Edward brings more than 20 years of experience in executive finance and operations leadership in the biotechnology industry to Benitec’s Board of Directors. Mr. Smith currently serves as the Chief Financial Officer of Marinus Pharmaceuticals (Nasdaq: MRNS), a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders. Prior to the start of his tenure at Marinus Pharmaceuticals in 2013, Mr. Smith served as the CFO of PolyMedix, and before his time at PolyMedix he served as the executive director of finance at InKine Pharmaceutical Company
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma commented on Mr. Smith’s appointment, Edward’s extensive background in finance and operations in the biotherapeutics space will make him an exceptional contributor to the Board. We are excited to welcome him as a director.
The price moved ahead of 13.38% from the mean of 20 days, -7.28% from mean of 50 days SMA and performed -31.27% from mean of 200 days price. Company’s performance for the week was 15.86%, 16.24% for month and YTD performance remained -20.69%.